Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 18/20 | 0.75 |
| ▸ | JAK2 | O60674 | 5/20 | 0.75 |
| ▸ | JAK1 | P23458 | 3/20 | 0.74 |
| ▸ | STAT3 | P40763 | 1/20 | 0.68 |
| ▸ | STAT1 | P42224 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26041689 | 0.91 | TYK2 (0.78) | TYK2JAK2JAK1STAT3STAT1 | |
| Cravacitinib SCHEMBL21091048 | 0.86 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Cravacitinib SCHEMBL30465860 | 0.86 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL16712842 | 0.85 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL26045198 | 0.85 | TYK2 (0.71) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL26042126 | 0.84 | TYK2 (0.57) | TYK2JAK2JAK1STAT3JAK3 | |
| SCHEMBL23637953 | 0.84 | TYK2 (0.58) | TYK2JAK2JAK1 | |
| SCHEMBL28647547 | 0.83 | JAK2 (0.74) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22647283 | 0.83 | TYK2 (0.76) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL23637843 | 0.82 | TYK2 (0.59) | TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | TYK2 1/4885JAK2 4/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.